We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Announcement that Novo Nordisk is buying DRNA at an 80% premium, so other RNAi plays (ALNY, ARWR, SLN) rise based on a view that they might also be in Big Pharma's sights. Also, likely to be some DRNA holders taking profits and reinvesting elsewhere in RNAi because they like the space.
https://investors.dicerna.com/news-releases/news-release-details/novo-nordisk-acquire-dicerna
It did rise by 9% a few weeks ago and like today, it didn`t hold up but still a good rise.
What's going on here today then? Shame they are moving to the Nas...
As far as I remember and I may have it wrong but my shares in another company that went over to the NAS, couldn`t be held in an ISA but come next week I will check with Barclays. Still looks very promising with that sort of level of investment, so still hopeful. GLA
The reason for the move up now known.
Mind, moving to the Nas only from here could be complex for some holders. I don't have an ISA
From Adfn bb
No advice intended but my understanding is that the SIPP rules (AJ Bell and Interactive Investor) are down to provider policy. HL as far as I can see is prepared to let you buy and sell in the SIPP post-delisting. The issue AJ Bell refer to and (as I understand it) the reason ADS's can't be held in an ISA post-delisting is that the ADS's are not "shares", they are effectively derivatives with the underlying investment being the Silence ordinary shares, which will be unlisted. It seems crazy (to me) given the Nasdaq listing for the ADS's - surely an unintended consequence? Today has been somewhat frustrating for me. HL came out with their instructions last night and they confirmed that they couldn't be held in an ISA. I expected a bit of a dive in the shareprice, the same as happened after the II instructions, and was ready to buy more. And there seems to have been a steady stream of sells, but today they seem to be almost exclusively AT trades rather than the O trades I would expect from HL clients selling up. And the price has held up very impressively so far.
Another piece falls into place or should I say 20,000,000, GLA
Some good movement here today on relatively small volume, was up over 9% for awhile, interesting times ahead hopefully. GLA
Little surpised that nobody posted this from the Evening Standard two weeks ago, but it is a very quiet board!
https://www.standard.co.uk/business/pharmaceuticals/silence-therapeutics-mark-rothera-interview-genetic-disease-mrna-b957141.html
Such small volume here each day, not a very wide spread either
OK, I'm in .... watch the markets soon lol
This seems a pretty good price don't you think? It looks like the trend is down though....ponder on buying now
Because it's an early-stage biotech in an exciting area with some big agreements signed. Have a read of the announcements they put out on deals with Mallinckrodt and Astrazeneca, and listen to today's webcast when a recording or transcript is put up to hear discussion of the market potential for their wholly-owned cardiovascular asset SLN360.
Mallinckrodt deal:
https://silence-therapeutics.com/investors/press-releases/press-releases-details/2019/Silence-collaboration-with-Mallinckrodt/default.aspx
Astrazeneca deal:
https://silence-therapeutics.com/investors/press-releases/press-releases-details/2020/Collaboration-with-AstraZeneca/default.aspx
Link to today's webcast and slide deck:
https://silence-therapeutics.com/investors/events-presentations/default.aspx
https://www.proactiveinvestors.co.uk/companies/news/957534/silence-therapeutics-hails-first-half--marked-by-strong-execution--957534.html
£5.6 mill revenues in 6 months?
how come its got an mcap, x 100 of that
Results out tomorrow, hopefully some positive news. GLA
Up we go again I am waiting for 20 pounds
Just seems to be getting better and perhaps some more movement North. GLA
It's it a rise or just oscillation? Nice news this morning though!
I thought I was the only shareholder ....lol Good seeing another decent rise and with this conference coming soon, maybe we will hear some positive news. GLA
Think I am the only shareholder in this company but nice to see another move up....yes it is
I love SLN. I have been in for many years and with all the support from US pharmaceuticals and great technological advances up, up and away imho. GLA.
All the action with my other holdings 88e... Dev and up sneaks sln with a nice rise today....think I'll have a beer
Would be good to get some updates for going forward, after small but fairly consistent rises of recent months, the last couple have been around 5% which is a nice change. GLA
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that its President and Chief Executive Officer, Mark Rothera, will present a company update at the virtual 2021 SVB Leerink Global Healthcare Conference on Friday, February 26th at 9:20 a.m. EST / 14:20 GMT.
A live webcast of the presentation can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcast will be available on the Company's website following the conference.
Hopefully some good news updates
I haven’t posted here in a while... but it looks like the new CEO and company is still ticking of the to do list. Quite a few things on the old list are now completed. The new guy in charge with this asset raise, has plenty of levers to pull imho. Likely he will push the GOLD platform and accelerate proprietary assets and SLN124/360 - but equally could announce a deal with takeda in coming weeks/months. Plenty of news items he can create to keep the shares here bid. Despite the covid interruption amazingly this company has barely missed a beat following the ARWR playbook. I expect the new CEO to continue that effort - the current asset raise reinforces my belief in the new CEO and the company.
My list looks something like - input always welcome
* Quark results as always delayed... Q1
* Takeda transition to an actual deal Q2
* Sln124 results Q2
* SLN124/360 results 2H
* Announce other proprietary assets Q2
* possibly another pay to play deal like Takeda 2H
* Probably a collaboration deal with E-Therapeutics 2H 21
* Results of Novartis Inclisran Phase 3 data 21
* Possible takeover of ARWR at a premium. 21
* MNK making another milestone payment 21
* Deal for SLN360 22
* List in the US Sep DONE
* New CEO end of Q3v DONE
* File IND for SLN360 Q4 DONE
* Strategic biotech investors DONE
*Mnk bankruptcy DONE
* MNK executing other options on 2 complement assets DONE